Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Pharmalot: U.S. Supreme Court Says Pharmaceutical Industry Must Pay for Drug Take-Back Programs

New York, NY, May 27, 2015 The Wall Street Journal’s Pharmalot blog reports that, in a setback to drug makers, the U.S. Supreme Court yesterday denied an industry request to review a lawsuit filed over a drug take-back program in Alameda County, California.

The pharmaceutical industry had been fighting a three-year-old ordinance that requires drug makers to underwrite the costs of a program in which consumers can drop off unwanted medicines.

Fearing still more local governments would pass such ordinances and create added expenses, three industry trade groups — the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO) and the Generic Pharmaceutical Association (GPhA) — filed a lawsuit and argued the local law was unconstitutional. 

In their view, the Alameda ordinance violates interstate commerce and also discriminates against out-of-state companies by unfairly shifting costs to drug makers.  The three trade groups had lost two previous rounds in court.

 

Experts say the U.S. Supreme Court’s May 26 decision to let the Alameda ordinance stand may mean that other counties and cities are more likely to consider establishing take-back programs that require drug makers to pick up the tab.

Pharmalot notes that since Alameda passed its ordinance, in fact, three other counties — two in California and one in Washington — have adopted similar laws.

For the full Pharmalot story, click here.

Pharmalot, a Wall Street Journal blog and a rich source of biopharma sector news, explores the fast-moving, complicated world that develops and markets medicines — and the drug makers that are attempting to replenish their pipelines while grappling with pricing and regulatory dictates, among many other challenges.

You may also follow Pharmalot on Twitter at @Pharmalot.